Delivering Results from Development Themes for High-Performance, High-Value-Added Products
First written in FY2016. 23 of 34 entries say "Restated". Latest entry: FY2026.
53 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In areas including additives for plastics and cosmetic ingredients, progress was made in commercializing priority themes, expanding commercial results, and advancing commercialization. In areas including electronic information materials and chemicals for civil engineering and construction, the company is also strengthening its efforts to develop environmentally friendly products.」
Commercialization and expansion of commercial results for priority themes advanced across multiple fields, while efforts to strengthen the development of environmentally friendly products in electronic information materials and chemicals for civil engineering and construction were also indicated. - FY2026-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥941 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company continued its R&D activities and recorded R&D expenses of ¥941 million for the interim consolidated accounting period. It explained that there had been no material changes in the status of these activities. - FY2025AdvancedAnnual report
「To accelerate problem-solving and the development of new technologies by combining the diverse technologies across multiple fields and product types that are one of the company's strengths, the company organized cross-site and cross-disciplinary working groups as needed, concentrated its research resources on priority themes, and advanced these initiatives. As a result, it achieved results including the establishment of production technologies for new products related to resin emulsions and the development of products related to additives for plastics.」
The company continued to concentrate research resources on priority themes through cross-site and cross-disciplinary working groups, achieving results in establishing production technologies for resin emulsions and developing additives for plastics. R&D expenses were also ¥1,892 million, equivalent to 3.5% of net sales. - FY2025-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥927 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company continued its R&D activities and recorded R&D expenses of ¥927 million for the interim consolidated accounting period. It explained that there had been no material changes in the status of these activities. - FY2024-Q3RestatedAnnual report
「The Group's total R&D expenses for the cumulative third quarter were ¥1,398 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company continued its R&D activities and recorded R&D expenses of ¥1,398 million for the cumulative third quarter. It explained that there had been no material changes in the status of these activities. - FY2024-Q2RestatedAnnual report
「The Group's total R&D expenses for the cumulative second quarter were ¥924 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and recorded R&D expenses of ¥924 million for the cumulative second quarter. It explained that there had been no material changes in the status of these activities. - FY2024-Q1RestatedAnnual report
「The Group's research and development expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥456 million. There were no significant changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
The company continued its R&D activities and recorded R&D expenses of ¥456 million for the cumulative first quarter. It explained that there had been no material changes in the status of these activities. - FY2023AdvancedAnnual report
「During the consolidated fiscal year, personnel equivalent to 15% of the workforce were allocated to research and development, which focused on functional chemicals including surfactants, resins, chemical products and specialty chemicals. Total research and development expenditure was ¥1,783 million, equivalent to 3.2% of net sales.」
15% of personnel and ¥1,783 million in research and development expenditure, equivalent to 3.2% of net sales, were allocated to research and development. Multiple development products, including photosensitive resins for precision processing, resins for next-generation semiconductors, urethane resins and sizing agents for glass fibers, led to sales and adoption. - FY2023-Q3RestatedAnnual report
「The Group's research and development expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥1,340 million. There were no significant changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative third quarter totaling ¥1,340 million. The company stated that there were no significant changes in the status of the activities. - FY2023-Q2RestatedAnnual report
「The Group's research and development expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥883 million. There were no significant changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
Research and development activities continued, and ¥883 million in research and development expenditure was recorded for the cumulative second quarter. The company stated that there were no significant changes in the status of the activities. - FY2023-Q1RestatedAnnual report
「The Group's research and development expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥438 million. There were no significant changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
Research and development activities continued, and ¥438 million in research and development expenditure was recorded for the cumulative first quarter. There were no significant changes in the status of the research and development activities. - FY2022AdvancedAnnual report
「Total research and development expenditure was ¥1,732 million, equivalent to 3.5% of net sales.」
15% of personnel and ¥1,732 million in research and development expenditure, equivalent to 3.5% of net sales, were allocated to research and development, and multiple products, including raw materials for household detergents, raw materials for concrete admixtures, and photosensitive resins for precision processing for next-generation semiconductors, led to sales and adoption. - FY2022-Q3RestatedAnnual report
「The Group's research and development expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥1,288 million. There were no significant changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The company reported research and development expenditure of ¥1,288 million for the cumulative third quarter and stated that there were no significant changes in its research and development activities. - FY2022-Q2RestatedAnnual report
「The Group's research and development expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥849 million. There were no significant changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
Research and development activities continued, and ¥849 million in research and development expenditure was recorded for the cumulative second quarter. There were no significant changes in the status of the research and development activities. - FY2022-Q1RestatedAnnual report
「The Group's research and development expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥420 million. There were no significant changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative first quarter totaling ¥420 million. There were no significant changes in the status of the activities. - FY2021-Q3RestatedAnnual report
「The Group's research and development expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥1,208 million. There were no significant changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative third quarter totaling ¥1,208 million. There were no significant changes in the status of the activities. - FY2021-Q2RestatedAnnual report
「The Group's research and development expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥801 million. There were no significant changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative second quarter totaling ¥801 million. There were no significant changes in the status of the activities. - FY2021-Q1RestatedAnnual report
「Group-wide R&D expenses for the three-month period were ¥397 million. There were no material changes in the status of our group’s R&D activities during the three-month period.」
Research and development activities continued, with research and development expenditure for the cumulative first quarter totaling ¥397 million. There were no significant changes in the status of the research and development activities. - FY2020AdvancedAnnual report
「During the consolidated fiscal year, personnel equivalent to 15% of the workforce were allocated to research and development, which focused on functional chemicals including surfactants, resins, chemical products and specialty chemicals. Total research and development expenditure was ¥1,644 million, equivalent to 3.9% of net sales.」
15% of personnel and ¥1,644 million in research and development expenditure, equivalent to 3.9% of net sales, were allocated to research and development, and new products including personal care ingredients, construction chemicals, pulp and paper chemicals, resins for the electronics and information industries, and acrylates led to sales. - FY2020-Q3RestatedAnnual report
「The Group's research and development expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥1,239 million. There were no significant changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative third quarter totaling ¥1,239 million. There were no significant changes in the status of the activities. - FY2020-Q2RestatedAnnual report
「The Group's research and development expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥823 million. There were no significant changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative second quarter totaling ¥823 million. There were no significant changes in the status of the activities. - FY2020-Q1RestatedAnnual report
「The Group's research and development expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥416 million. There were no significant changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative first quarter totaling ¥416 million. There were no significant changes in the status of the research and development activities. - FY2019AdvancedAnnual report
「We achieved results including the commercialization of a major development theme for resins for precision processing in the electronic information industries, the commercialization of cosmetic ingredients such as skincare polymers in the personal care ingredients segment, and the commercialization of raw materials for concrete admixtures used in low-carbon, low-environmental-impact construction materials in the construction chemicals segment.」
A major development theme for resins for precision processing, skincare polymers and other products, and raw materials for low-carbon, low-environmental-impact construction materials were commercialized. Research and development expenditure was ¥1,597 million, equivalent to 3.5% of net sales. - FY2019-Q3RestatedAnnual report
「The Group's research and development expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥1,184 million. There were no significant changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative third quarter totaling ¥1,184 million. There were no significant changes in the status of the activities. - FY2019-Q2RestatedAnnual report
「The Group's research and development expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥791 million. There were no significant changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative second quarter totaling ¥791 million. There were no significant changes in the status of the activities. - FY2019-Q1RestatedAnnual report
「The Group's research and development expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥395 million. There were no significant changes in the status of the Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative first quarter totaling ¥395 million. There were no significant changes in the status of the activities. - FY2018-Q3RestatedAnnual report
「The Group's research and development expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥1,118 million. There were no significant changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative third quarter totaling ¥1,118 million. There were no significant changes in the status of the activities. - FY2018-Q2RestatedAnnual report
「The Group's research and development expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥736 million. There were no significant changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
Research and development activities continued, with research and development expenditure for the cumulative second quarter totaling ¥736 million. There were no significant changes in the status of the activities. - FY2017AdvancedAnnual report
「During the consolidated fiscal year, research and development activities were conducted at the Company's two research and development facilities, the Oppama Research Center and the Chiba Research Center. Total research and development expenditure was ¥1,427 million, equivalent to 3.7% of net sales. Newly developed resins for precision processing were commercialized and led to sales. For acrylates, primarily used in electronic information-related materials, newly developed products tailored to the requirements of overseas customers were commercialized and led to sales.」
¥1,427 million, or 3.7% of net sales, was invested in research and development, and multiple new products, including resins for precision processing and acrylates, led to sales and adoption. - FY2017-Q3AdvancedAnnual report
「Resins for precision processing in the electronics and information industries posted an increase in revenue, supported by higher sales of newly developed products. The Group's research and development expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥1,082 million. There were no significant changes in the status of the Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
Specific results were reported showing that increased sales of newly developed products contributed to higher revenue. Research and development activities continued, with research and development expenditure for the cumulative third quarter totaling ¥1,082 million. - FY2017-Q2RestatedAnnual report
「The Group's research and development expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥714 million. There were no significant changes in the status of the Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
The continuation of research and development activities and research and development expenditure of ¥714 million for the cumulative second quarter of the current consolidated fiscal year were reported. - FY2016First statedAnnual report
「③ Commercialization of development themes for high-performance, high-value-added products」
Making research and development themes contribute to sales and earnings is a priority issue.